louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03168841: Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Official title: Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Onychomycosis
Lead sponsor: Western University of Health Sciences
Sponsor class: OTHER
First posted: 2017-05-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Onychomycosis, a common pathology of the toenails, is even more prevalent among diabetic subjects. Nearly 26 million Americans suffer from diabetes, and approximately one-third of subjects with diabetes have toenail onychomycosis. Numerous studies have addressed the efficacy and safety of both topical and oral antifungal treatment options for onychomycosis in diabetic subjects. However, no study to date has specifically addressed the efficacy and safety of efinaconazole among diabetic subjects.

The objective of this noncomparative, uncontrolled study is to determine the efficacy of topical efinaconazole 10% for toenail onychomycosis among subjects with diabetes mellitus. Specific indicators to measure efficacy of treatment will be the mycological cure rate, complete cure rate, and treatment success. Furthermore, an additional goal of the study is to gain knowledge of safety in the setting of a cohort of diabetic subjects


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of onychomycosis confirmed through positive KOH stain or positive mycologic culture findings.
* Involvement of at minimum 20% of the target great toenail.

Exclusion Criteria:

* Diagnosis of a nondermatophyte fungus infection, diagnosis of proximal subungual onychomycosis, diagnosis of superficial white onychomycosis
* Diagnosis of peripheral arterial disease or anatomic abnormalities of the target toenail
* Inability to follow through with all requisite office visits
* Routine use of a systemic corticosteroid, routine use of a systemic immunomodulator, or history of systemic antifungals within the prior five years.
* Active interdigital tinea pedis refractory to topical antifungal treatments
* Known hypersensitivity to efinaconazole
* Use, within the month preceding screening, of: topical antifungal agents, topical anti-inflammatory agents to the toes
* Any history of oral systemic antifungal with known activity against dermatophytes

Primary outcomes:
measure: Primary Endpoint - Efficacy
timeFrame: 50 weeks
Secondary outcomes:
measure: Secondary Endpoint - Efficacy
timeFrame: 50 weeks
measure: Secondary Endpoint - Efficacy
timeFrame: 50 weeks
measure: Secondary Endpoint - Safety (Occurrence of Adverse Events: Type and Frequency)
timeFrame: 50 weeks
Other outcomes:
Locations:
city: Pomona
country: United States
facility: Western University of Health Sciences
state: California
Study officials:
References:
Clinical trial NCT03159741: Investigation of GLP-2 Mechanism of Action (GA-8)
Official title: Investigation of GLP-2 Mechanism of Action (GA-8)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: Hvidovre University Hospital
First posted: 2017-05-19
Enrollment: 8
Sex: MALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit the bone resorption. However, the mechanism is unknown. In the present study we will investigate the mechanism of action using a receptor specific inhibitor.


Eligibility criteria: Inclusion Criteria:

* Healthy, 20 to 40 years old, caucasian, BMI 18,5 to 24,9 kg/m2

Exclusion Criteria:

* Chronic disease, smoking, medication, weight change more than 3 kg whitin the last 3 months, overweight surgery, intestinal surgery, Hgb\<8,0 mmol/L, decreased renal function.

Primary outcomes:
measure: C-terminal telopeptide (CTX)
timeFrame: -30 to 240 min.
Secondary outcomes:
measure: N-terminal propeptide of type 1 procollagen (P1NP)
timeFrame: -30 to 240 min.
measure: Osteocalcin (OC)
timeFrame: -30 to 240 min.
measure: Parathyroid hormone (PTH)
timeFrame: -30 to 240 min.
measure: Osteoprotegerin (OPG)
timeFrame: -30 to 240 min.
measure: Glucose-dependent insulinotropic polypeptide (GIP)
timeFrame: -30 to 240 min.
measure: Glukagon-like peptide-1 (GLP-1) and glukagon-like peptide-2 (GLP-2)
timeFrame: -30 to 240 min.
measure: Glukagon and pancreatic polypeptide (PP)
timeFrame: -30 to 240 min.
measure: Glucose
timeFrame: -30 to 240 min.
measure: Insulin/c-pep.
timeFrame: -30 to 240 min.
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
affiliation: University of Copenhagen
name: Mette Rosenkilde, MD
role: STUDY_DIRECTOR
affiliation: Hvidovre University Hospital
name: Sten Madsbad, MD
role: STUDY_DIRECTOR
References:
citation: Skov-Jeppesen K, Svane MS, Martinussen C, Gabe MBN, Gasbjerg LS, Veedfald S, Bojsen-Moller KN, Madsbad S, Holst JJ, Rosenkilde MM, Hartmann B. GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone. 2019 Aug;125:178-185. doi: 10.1016/j.bone.2019.05.014. Epub 2019 May 15.
Clinical trial NCT02955641: Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy
Official title: Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Glaucoma, Closed-Angle
Glaucoma, Narrow-Angle
Glaucoma, Angle-Closure
Keywords: Laser peripheral iridotomy
topical anti-inflammatory drops
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2016-11-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and need for prescribing anti-inflammatory topical drops to patients undergoing laser peripheral iridotomy.

Detailed description: Primary closed angle glaucoma is responsible to almost half glaucoma related blindness around the world. Laser peripheral iridotomy (LPI) is a common and simple treatment used for both treatment and prevention of acute angle closure event.

Anti-inflammatory drops are commonly prescribed to patients undergoing LPI in order to prevent or reduce post-treatment discomfort. However, to date, there are no specific guidelines for post LPI anti-inflammatory treatment, nor sufficient clinical evidence regarding the efficacy of such treatment.

In the current study, the investigators aim to evaluate the effect of topical steroids and non-steroidal anti-inflammatory drugs (NSAIDs) on post LPI symptoms and inflammation markers.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of primary narrow/closed angle by gonioscopy
* Able to give consent
* Ability to attend follow-up visits

Exclusion Criteria:

* Corneal disease preventing sufficient evaluation of the angle
* Secondary closed angle (e.g. uveitis related)
* Pregnant women
* Previous eye surgery other than laser refractive correction

Primary outcomes:
measure: Pain score
timeFrame: At four days post LPI treatment
measure: Symptoms score
timeFrame: At four days post LPI treatment
Secondary outcomes:
measure: Grading of cells in the anterior chamber
timeFrame: At four days post LPI treatment
measure: Patency of LPI by visualisation
timeFrame: up to 30 days post LPI treatment
measure: Grading of flare in anterior chamber
timeFrame: At four days post LPI treatment
Other outcomes:
Locations:
city: Tel HaShomer
country: Israel
facility: Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Ari Leshno, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02832141: Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems
Official title: Effect of Thoracic Spine Mobilization on Skin-blood Flow, Erythema and Sympathetic Nervous Systems
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erythema
Keywords: Skin blood flow
Skin redness
Sympathetic nervous system
Regional Blood Flow
Lead sponsor: Bern University of Applied Sciences
Sponsor class: OTHER
First posted: 2016-07-14
Enrollment: 14
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy person between 20 and 30 years.

Brief summary: This pilot study aims to i) represents the feasibility of the study design and ii) to point out acute effects of thoracic spine mobilization on skin-blood flow, erythema and the sympathetic nervous system.


Eligibility criteria: Inclusion Criteria:

* age 20 - 30 years
* healthy persons

Exclusion Criteria:

* current pain
* blood pressure medications
* osteoporosis
* cardiac or neurological symptoms
* pregnancy
* thromobosis

Primary outcomes:
measure: Feasibility: Adherence of recruited participants
timeFrame: Every 4 weeks up to 2 years
measure: Feasibility of the investigating procedure
timeFrame: Every 4 weeks up to 2 years
measure: Feasibility of the mobilization intervention from posterior-to-anterior on thoracic vertebrae
timeFrame: Every 4 weeks up to 2 years
measure: Feasibility of the mobilization intervention from anterior-to-posterior on thoracic vertebrae
timeFrame: Every 4 weeks up to 2 years
Secondary outcomes:
measure: Rate of heart rate variability (HRV)
timeFrame: Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention
measure: Rate of systolic blood pressure value (mmHg)
timeFrame: Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention
measure: Rate of diastolic blood pressure value (mmHg) changes
timeFrame: Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention
measure: Rate of heartbeat frequency
timeFrame: Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention
measure: Rate of skin-blood flow variation
timeFrame: Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention
measure: Rate of erythema
timeFrame: Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Bern University of Applied Science, Department Health
Study officials:
affiliation: Bern University of Applied Science, Departement Health
name: Jan Taeymans, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rogan S, Taeymans J, Clarys P, Clijsen R, Tal-Akabi A. Feasibility and effectiveness of thoracic spine mobilization on sympathetic/parasympathetic balance in a healthy population - a randomized controlled double-blinded pilot study. Arch Physiother. 2019 Dec 9;9:15. doi: 10.1186/s40945-019-0067-2. eCollection 2019.
Clinical trial NCT00783341: Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
Official title: An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2008-10-31
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.


Eligibility criteria: Inclusion

1. Men or women of non childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening.
2. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥50 kg.
3. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital sign measurements, and 12-lead electrocardiogram (ECG).
4. Serum creatinine level must be less than 1.30 mg/dL. (Normal range: 0.44 to 1.24 mg/dL.)
5. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.

Exclusion

1. Presence or history of any disorder that may prevent the successful completion of the study.
2. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
3. Any surgical or medical condition that may interfere with the distribution, metabolism, or excretion of the test article.
4. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.
5. Any history of clinically important cardiac arrhythmias.
6. Familial history of long QT syndrome or unexpected cardiac death.
7. History of drug abuse within 1 year before study day 1.
8. History of alcoholism within 1 year before study day 1.

Primary outcomes:
measure: Safety as determined by reported adverse events, laboratory test results, and ECGs
timeFrame: 3 weeks
Secondary outcomes:
measure: Pharmacokinetic parameters
timeFrame: 9 days
Other outcomes:
Locations:
city: Philadelphia
country: United States
state: Pennsylvania
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01203241: Benefit of Left Atrial Roof Ablation in Paroxysmal Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Drug-refractory Paroxysmal Atrial Fibrillation
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
First posted: 2010-09-16
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to assess whether left atrial roof ablation adds any benefit in the arrhythmia-free probability after paroxysmal atrial fibrillation ablation.


Eligibility criteria: Inclusion Criteria:

* Drug-refractory paroxysmal atrial fibrillation

Exclusion Criteria:

* Hypo or hyperthyroidism
* Implantable defibrillation or pacemaker implanted
* Moderate or severe mitral valve disease or mitral prosthetic valve
* Ejection fraction less than 30%
* Left atrial anteroposterior diameter more than 50 mm.
* Previous atrial fibrillation ablation
* Left atrium thrombus
* Current infective disease or sepsis
* Pregnant women
* Current unstable angor
* Acute myocardial infarction in last 3 months
* Atrial fibrillation secondary to ionic disturbance, thyroids disease or secondary to any other reversible or non cardiovascular disease
* Reduced expectancy of life (less than 12 months)
* Patient participating in another clinical study that investigates a drug or device
* Psychologically unstable patient or denies to give informed consent

Primary outcomes:
measure: Freedom from atrial arrhythmias without antiarrhythmic drugs
timeFrame: 1-year follow-up
Secondary outcomes:
measure: Freedom from atrial arrhythmias with or without antiarrhythmic drugs
timeFrame: 1-year follow-up
measure: Presence of any complications in the acute phase or during follow-up
timeFrame: 1-year follow-up
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clinic Universitari
Study officials:
References:
citation: Arbelo E, Guiu E, Ramos P, Bisbal F, Borras R, Andreu D, Tolosana JM, Berruezo A, Brugada J, Mont L. Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study. J Am Heart Assoc. 2014 Sep 5;3(5):e000877. doi: 10.1161/JAHA.114.000877.
Clinical trial NCT02713841: Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes
Official title: Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects With Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Type 1 Diabetes Mellitus
Lead sponsor: Dance Biopharm Inc.
Sponsor class: INDUSTRY
First posted: 2016-03-21
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study was to compare the pharmacokinetic (PK) response after inhaled insulin administration with 3 different inhalation regimens and with subcutaneous insulin administration.

Detailed description: This first-in-human trial investigated the optimal particle size for absorption of Dance-501, an aerosolized liquid human insulin for inhalation (INH).

Twelve subjects with type 1 diabetes received an INH dose (50 IU) using an inhaler on 4 visits and 6 U insulin lispro (LIS) sc on a separate visit to assess relative bioavailability (FREL) of INH. The inhaler was configured to generate insulin aerosol particles sized 3.5-4.0 μm (low output mesh; LOM), 4.3-4.8 μm (medium output mesh; MOM) or 5.0-5.5 μm (high output mesh; HOM) during low inspiratory flow. To assess within subject variability, MOM was used twice. Pharmacokinetics (PK) were measured up to 8 hours after dosing.

Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes mellitus treated with multiple daily insulin injections or continuous subcutaneous insulin infusion and total daily insulin dose less than 1.2 units/kg/day.
* Body mass index 18.0 - 28.0 kg/m2.
* Hemoglobin A1c less than or equal to 9%.
* Forced vital capacity and forced expiratory volume in one second at least 75% of predicted normal values for race, age, gender and height.
* Fasting C-peptide less than 0.3 nmol/L.

Exclusion Criteria:

* Subjects with any condition possibly affecting drug absorption from the lung, in particular subjects with decreased lung function or subjects taking bronchodilators or subjects who smoke.
* Active or chronic pulmonary disease.
* Any clinically significant major disorders other than diabetes mellitus.
* Decompensated heart failure at any time or angina pectoris within the last 12 months or acute myocardial infarction at any time.
* Proliferative retinopathy or severe neuropathy.

Primary outcomes:
measure: Area under the insulin human / insulin lispro concentration-time curve from 0 to 8 hours (AUCINS,0-8h)
timeFrame: 0 to 8 hours
measure: Bioavailability
timeFrame: 0 to 8 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Profil Institut für Stoffwechselforschung GmbH
name: Tim Heise, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05748041: Multiparametric Approach to Identify a CMR-based Tricuspid Regurgitation Classification
Official title: Multiparametric Approach to Identify a CMR-based Tricuspid Regurgitation Classification
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Tricuspid Regurgitation Congenital
Lead sponsor: IRCCS Policlinico S. Donato
Sponsor class: OTHER
First posted: 2023-02-28
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of tricuspid regurgitation.

Brief summary: The aims of this study are:

1. to explore a novel 2D-Cardiovascular magnetic resonance (CMR) indirect method for tricuspid regurgitation (TR) quantification (ATRIAL method) relying on right atrium variables, and assess its agreement with the traditional indirect method (involving right ventricle variables) and the direct method (based on through-plane phase contrast (PC) sequences on the tricuspid valve);
2. to assess the agreement of TR volume (RVol) and regurgitant fraction quantification from 2D-CMR methods with transthoracic echocardiography and 4DF-CMR methods;
3. to assess the diagnostic performance of 2D-CMR in classifying TR, in terms of RVol and regurgitant fraction, with respect to echocardiographic transthoracic echocardiography grades.


Eligibility criteria: Inclusion Criteria:

* patients aged ≥ 18 years with the diagnosis of al least mild-degree tricuspid regurgitation, who:
* patients that are scheduled for a Cardiovascular Magnetic Resonance examination in our Institution

Exclusion Criteria:

* Patients with previous surgical or transcatheter interventions on the tricuspid valve
* Patients with Ebstein's disease
* Subjects with pace-maker or intracardiac defibrillator
* Subjects with intrabody ferromagnetic material precluding patient's safety
* Patients with claustrophobia or breath-holding precluding an adequate CMR images quality
* Pregnant women

Primary outcomes:
measure: 2D-CMR (different methods)
timeFrame: 3 years
Secondary outcomes:
measure: RVol and RF
timeFrame: 3 years
Other outcomes:
measure: TTE, performed within 30 days from the CMR examination
timeFrame: 3 years
Locations:
city: San Donato Milanese
country: Italy
facility: IRCCS Policlinico San Donato
state: Milano
Study officials:
References:
Clinical trial NCT05537441: Precision Vaccine Promotion in Underserved Populations
Official title: Precision Vaccine Promotion in Underserved Populations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Influenza
Vaccine Hesitancy
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
name: University of California, Los Angeles
name: Los Angeles County Department of Public Health
First posted: 2022-09-13
Enrollment: 228831
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Previous studies have shown that low-cost, behavioral nudges through texting can increase influenza vaccination uptake compared to usual care. However, there are limited studies that evaluate the effect of decreasing barriers to scheduling, especially within safety net populations. The setting for this study, DHS, is the second largest public delivery system in the country and serves approximately half a million diverse patients that are eligible for vaccinations annually. This pilot study (one arm in a larger randomized controlled trial) will examine the effect of text messages highlighting MediCal health plan transportation resources (vs standard text messaging) on influenza vaccination rates in adults during the 2022-2023 flu season.


Eligibility criteria: Inclusion Criteria:

* Los Angeles County Department of Health Services (LACDHS) primary care patients over 6 months of age

Exclusion Criteria:

* LACDHS patients less than 6 months of age

Primary outcomes:
measure: Number of Participants Vaccinated at the End of the Campaign Period
timeFrame: 6 months
Secondary outcomes:
measure: Heterogeneity of Treatment Effects for Demographics
timeFrame: 6 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Los Angeles County Department of Health Services
state: California
Study officials:
affiliation: University of Southern California
name: Daniella Meeker, PhD
role: PRINCIPAL_INVESTIGATOR
References: